Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies

Conclusion: The variations in estradiol and progesterone levels observed in compounded hormone therapy formulations justify concerns regarding risks as a result of variability, which have been outlined by The North American Menopause Society, the American College of Obstetricians and Gynecologists, and the US Food and Drug Administration (FDA) in their statements regarding compounded hormone use. These data support the need for an US FDA-approved bioidentical hormone therapy. Video Summary: Supplemental Digital Content 1, http://links.lww.com/MENO/A425.
Source: Menopause - Category: OBGYN Tags: Original Articles Source Type: research